t cell lymphoma e g7 ova  (ATCC)

Journal: Cell Reports Medicine

Article Title: Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

doi: 10.1016/j.xcrm.2026.102699

Figure Lengend Snippet: Rational modulation of tumor microenvironment enhances therapeutic responsiveness to αOX40-based immunotherapy (A–D) OX40-humanized mice bearing subcutaneous MC38 (A), B16 (B), E.G7 (C), or KPC (D) tumors ( n = 5–7 mice per group). Tumor growth curves (numbers indicate complete cures) and Kaplan-Meier survival for each model. Treatments: MPLA+IFN-γ ( i.t. , intratumoral); Combo: MPLA+IFN-γ ( i.t. , intratumoral) + αOX40 ( i.p. , intraperitoneal). (E) Study schema of secondary tumor challenge in MC38 model treated with Combo. (F) Tumor progression and survival outcomes following secondary tumor challenge. Growth kinetics of re-implanted tumors in tumor-cleared mice (previously cured by therapy) versus treatment-naive wild-type controls (left). Kaplan-Meier survival plot (right) ( n = 13 mice per group). (G) Systemic immunity evaluation schema with bilateral MC38 bearing mice were treated with Combo, αOX40, and control. (H) Tumor growth curves and survival plots of (G) ( n = 6–7 mice per group). Data are shown as means ± SD from one of two independent experiments (A–D, F, and H). Statistical significance was determined using log rank test (A–H). n.s., not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: E.G7 Mouse T lymphoma Cell , ATCC , Cat# CRL-2113.

Techniques: Control

Journal: Molecular Therapy Advances

Article Title: Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release

doi: 10.1016/j.omta.2026.201698

Figure Lengend Snippet: Low-dose, antigen-encoding pDNA-LNP improved the therapeutic efficacy of DNA immunization in E.G7-OVA tumor-bearing mice B6 mice were implanted with E.G7-OVA-PDL1hi tumors on day 0. Mice were immunized intradermally on days 1, 8, and 15 with the following: pTVG4 (100 μg), pTVGsOVA (100 μg), pTVGsOVA-LNP (10 μg), pTVGsOVA (100 μg) + pTVG4-LNP (10 μg), or pTVGsOVA (100 μg) + pTVGsOVA-LNP (10 μg) as depicted in the study schema in (A). Shown are (B) individual mouse tumor growth curves, (C) average tumor growth curves per group, and (D) survival curves. ∗∗∗ p < 0.001 as assessed by repeated measures two-way ANOVA comparing the dark blue line (pTVGsOVA-LNP + pTVGsOVA) to the indicated color-coded group (C) or ∗ p < 0.05 as assessed by log rank test (D). N = 5 mice per group (pTVG4, pTVGsOVA, and pTVGsOVA-LNP) or N = 7 mice per group (combination groups). Results shown are representative of a similar independent experiment shown in .

Article Snippet: The E.G7-OVA cell line was originally purchased from ATCC (#CRL-2113) and transduced to express PD-L1, as described previously.

Techniques: Drug discovery